Driving progress in Cell & Gene Therapy

Now with 19 member companies and 183 subject matter experts, the BioPhorum Cell & Gene Therapy (C&GT) Phorum has made great strides since its formation in 2018. The Phorum has a growing list of goals for the next 12–18 months and the team will use its combined strength to accomplish these.

The Phorum aims to support the faster delivery of C&GT products to market, by lowering business and supply chain risk, and accelerating improvements and the adoption of technical solutions. Do you want to be part of this drive and its impact on the industry?

At a meeting in April 2019 in Boston, US, the Phorum focused on two of the Phorum’s six workstreams: Raw Materials (Sourcing, Quality and Volume) and Validation. The meeting was a chance to reflect on the last six months and set a clear plan and direction for the future.

 

It was the first face-to-face meeting for many attendees, particularly those from companies new to the Phorum, and was a chance to build new relationships. It covered lots of subjects and helped accelerate the effort of the workstreams more than regular telephone calls.

The meeting was attended by 51 people over two days – a high level of attendance for such a new Phorum. The main goal was to focus the industry’s energies and mobilize the community to take advantage of new opportunities. Preparing sessions and case studies in advance helped keep engagement high and ensured knowledge and experience was shared.

The first day looked at the work of Raw Materials workstream, which discussed the key topics of Supplier Engagement, Material Performance and Risk Matrices.

The Supplier Engagement session generated a list of key suppliers with whom BioPhorum will engage, and a list of prioritized actions on how to improve supplier relationships. In particular, the attendees wanted to ensure a common understanding of the unique issues affecting the C&GT supply chain that differ from those of ‘standard’ biopharma manufacturing.

Material Performance looked at particulates, which is an area of increasing concern to the C&GT community. The emphasis was on actions to help understand the variety and extent of the source of particulates, and the risks they pose to the release of production batches.

Finally, the team reviewed its internal C&GT Risk Matrix, which covers the factors affecting the purchase and first-use of raw materials. It also discussed working with the Drug Substance Phorum, which has carried out work in raw material variance. While not focused on C&GT, its Risk Assessment Methodology document (awaiting publication), contains a lot of learning and practices that will be useful to the C&GT Phorum.

The second day concentrated on the Validation workstream and covered Contract Manufacturing Organization (CMO)/client interactions, C&GT-specific Validation Challenges, and Control Strategy and Process Validation.

The team reviewed the interfaces between CMOs and clients and documented the points where clear responsibilities and accountabilities are key. Clarifying and communicating these points will prove critical to building and maintaining successful relationships between biomanufacturers and CMOs.

Following the thought processes from the Raw Materials workstream sessions, the Validation team talked about the strategies and phased approach needed to cope with the limited variability of the raw materials available during development and manufacture. There are also unique considerations when using patient and donor cells, which may show both extreme variability and limited supply. Improved regulatory guidance and support for product validation will be driven by the stronger consortium voice of BioPhorum. Finally, the team discussed defining specifications using actual data, such as those for pre-clinical and process studies, and agreed on a broad approach to be taken.

Each day ended with the teams collating an action plan to help them achieve their goals.

The next meeting of the C&GT Phorum will take place in September 2019 and will focus on two other C&GT workstreams: Environmental Health & Safety/BioSafety, and Commercialization. The ‘working meeting’ format will be continued as the team looks to publish white papers and guidance notes, and collect survey data for these workstreams.

For more information about the Cell & Gene Therapy Phorum, and how to become a member, please contact Christelle@BioPhorum.com

Contact address

BioPhorum
The Gridiron Building
One Pancras Square
London
N1C 4AG

Newsletter subscribe

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.



© 2019 Biophorum Operations Group · All Rights Reserved

Registered Address: 5 Westbrook Court · 2 Sharrow Vale Road · Sheffield · S11 8YZ

Company Number 06794795 · VAT Number GB298617544

How the fast-start C&GT Phorum is delivering results

From a standing start in 2018, the BioPhorum Cell & Gene Therapy (C>) Phorum has made huge progress on a range of initiatives aimed at[...]

Read More
Driving progress in Cell & Gene Therapy

Now with 19 member companies and 183 subject matter experts, the BioPhorum Cell & Gene Therapy (C>) Phorum has made great strides since its formation[...]

Read More
Cell and Gene Therapy Phorum accelerates progress

The BioPhorum Cell & Gene Therapy Phorum has made significant progress since its creation in 2018 – from building networks and sharing knowledge to endorsing[...]

Read More
Sharing powerful collaboration data on the impact of resin cycling on viral clearance

A crucial issue for biotechnology products is that the mammalian cell lines commonly used in manufacturing are susceptible to viral contamination. Therefore, demonstration of viral[...]

Read More
Industry bioassay approach helps to shape the future

In 2018, members of the Development Group Bioassay workstream came together to write a best practices paper on bioassay development. We are delighted to announce[...]

Read More
Sharing ideas on forced degradation

“Forced degradation studies are an important part of the drug lifecycle process as they can inform many aspects of drug development,” said Jennifer Halley, Principal[...]

Read More
BioPhorum Anvisa support goes from strength to strength

There are many things that make a relationship work, such as trust, honesty and mutual respect. And a sign of a strong relationship is someone[...]

Read More
Delivering globally on in-line monitoring and real-time release

BioPhorum is increasing its focus on delivering against strategic goals of member companies as outlined in the BioPhorum Biomanufacturing Technology Roadmap. The first step in[...]

Read More
New and improved User Requirements Toolkit for single-use systems

To help customers and manufacturers achieve a ‘right first time’ implementation of single-use systems, BioPhorum launched a User Requirements Toolkit in June 2018. This includes[...]

Read More
PUPSIT – An update on BioPhorum/PDA work to develop a risk-based position
Read More
Driving the evolution of secondary packaging

How do we transition from large-batch manufacture to small-batch, high-value packaging runs?

Read More
Hi-tech ambitions for Fill Finish

The Fill Finish Phorum has recently embarked on a series of exciting and ambitious initiatives, exploring new technologies and processes to enhance the efficiency and[...]

Read More
Logistics collaboration hub: An opportunity for significant time and cost savings

Most biopharmaceutical manufacturers use a network of logistics service providers (LSPs) to deliver warehousing, transport and distribution services, and they are usually linked using customized,[...]

Read More
The ‘how to’ guide to implementing Agile in GxP

The publication of the Guidance on the use of Agile in a GxP Environment document in 2017 was well received.It described how the use of[...]

Read More
How smart is your maintenance?

Faster. Cheaper. Smarter. All companies are under pressure to achieve more with less, not least with their maintenance programs. But while ‘faster’ and ‘cheaper’ maintenance[...]

Read More
BioPhorum’s Maturity Assessment Tool gains momentum
Read More
Supply chain, forecasting and demand planning solutions gain momentum

The relationship between suppliers and manufacturers is one of the most crucial in biopharmaceutical manufacturing. This is especially the case when forecasting and supply planning.[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
BioPhorum blazes a trail tackling your buffer preparation bottlenecks

Buffers are critical inputs into all downstream processing steps associated with the manufacture of therapeutic proteins. The large volumes of buffer required present ongoing logistical[...]

Read More
How plug-and-play will help you glide through the biomanufacturing dance

It is pretty clear that automation can improve efficiency, track performance and liberate operators from mundane routines. But with it comes cost and time factors[...]

Read More
Delivering globally on in-line monitoring and real-time release

BioPhorum is increasing its focus on delivering against strategic goals of member companies as outlined in the BioPhorum Biomanufacturing Technology Roadmap. The first step in[...]

Read More
Slicing years off change implementation

As the first regulatory authority in Latin America to gain full membership of the International Council for Harmonization (ICH), the Brazilian Health Regulatory Agency (Anvisa)[...]

Read More
BioPhorum Regulatory Interaction: helping to open doors

To implement any change in the biopharmaceutical manufacturing industry it is important to engage with and collaborate with the regulators. Set up two years ago,[...]

Read More
Regulatory compliance: what lessons can be learned?

BioPhorum delivery of value from the disposables five-year plan - supplier change notifications for single-use systems

Read More
Navigating the maze of medical technology regulation: a solo voyage or a team effort?

Medical technology is a global business, generating annual revenues of over $400bn. The sector encompasses a broad range of technologies: from in-vitro diagnostics and diagnostic[...]

Read More

IaaS Cloud webinar recording play back
Read More
New BPIT guidance to align cloud services to regulatory requirements
Read More
Data Integrity and Agile Webinars to support industry response to regulators
Read More
How to validate informatics in CPV programs

The BioPhorum Continued Process Verification (CPV) and Informatics team has published a paper to support a risk-based approach for the validation of informatics systems for[...]

Read More
Continued Process Verification delivering real saving in time and money

More than 50 per cent of biopharma products on the market now have Continued Process Verification (CPV) plans in place.  Thanks to the CPV white[...]

Read More
A roadmap for the implementation of continued process verification

This article provides a roadmap draws on the content of the CPV case study to provide a step-by-step guide in a more accessible form.

Read More
How smart is your maintenance?

Faster. Cheaper. Smarter. All companies are under pressure to achieve more with less, not least with their maintenance programs. But while ‘faster’ and ‘cheaper’ maintenance[...]

Read More
Digital plant maturity model webinar replay
Read More
Digital Plant Maturity Model workstream to host webinar
Read More
New guidance available on Forecasting and Demand Planning to streamline supply chain performance
Read More
Changes to BioPhorum extractables protocol

The BioPhorum Extractables team has shown the benefits of great collaboration between biomanufacturers and suppliers – they agreed to significantly reduce extractables testing for single use[...]

Read More
Host cell proteins poster

This poster presented at the BEBPA Conference, San Francisco builds and consolidates the information currently available in the industry for assessing process risk from Host[...]

Read More
Host cell protein risk assessment, an industry approach

Host cell protein (HCP) constitutes a significant class of process-related impurities in biological drugs.

Read More
BEBPA risk assessment workshop
Read More
New and improved User Requirements Toolkit for single-use systems

To help customers and manufacturers achieve a ‘right first time’ implementation of single-use systems, BioPhorum launched a User Requirements Toolkit in June 2018. This includes[...]

Read More
BioPhorum blazes a trail tackling your buffer preparation bottlenecks

Buffers are critical inputs into all downstream processing steps associated with the manufacture of therapeutic proteins. The large volumes of buffer required present ongoing logistical[...]

Read More
How plug-and-play will help you glide through the biomanufacturing dance

It is pretty clear that automation can improve efficiency, track performance and liberate operators from mundane routines. But with it comes cost and time factors[...]

Read More
BioPhorum Anvisa support goes from strength to strength

There are many things that make a relationship work, such as trust, honesty and mutual respect. And a sign of a strong relationship is someone[...]

Read More

Share This

Share this

Share this post with your colleagues.